Autopsy report · NCT04900766
A Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Advanced Bone and Soft Tissue Sarcoma
Cause of deathFunding or business
“The sponsor has adjusted its R\&D strategy.”
Life of this trial
- Registered 3 months before it started.
- Ran for about 1 year 6 months before it stopped.
- 31 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- Sponsor type
- Industry
- Conditions
- Unresectable or Metastatic Bone and Soft Tissue Sarcoma
- Interventions
- Mitoxantrone Hydrochloride Liposome Injection
- Participants
- 31
- Sites
- 1
- Countries
- China
Trials that died the same way
- A Study of SHR3680 in Combination With SHR3162 in the Treatment of mCRPC
“The sponsor's R\&D strategy is adjusted.” - A Study to Assess the Efficacy and Safety of HRG2005 Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
“Sponsor's R\&D strategy adjusted.” - A Study of SHR-1702 Alone or With Camrelizumab in Participants With Advanced Relapsed/Refractory Solid Tumors
“Sponsor R \& D Strategy Adjustment” - Efficacy, Safety and Tolerability of PF-06687234 as Add-on Therapy to Infliximab in Active UC Subjects Not in Remission.
“The Sponsor changed R\&D strategy and priority.” - Study to Evaluate Safety and Efficacy of Carrimycin for Treatment of Severe Coronavirus Disease 2019 (COVID-19) in Hospitalized Patients
“sponsor strategy change”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.